Market Overview - The US stock market closed higher, with the Dow Jones and S&P 500 indices reaching all-time closing highs. The S&P 500 rose by 0.62%, the Nasdaq increased by 0.65%, and the Dow Jones gained 0.99% [3] - The core drivers of the market were semiconductor and AI-related stocks, particularly following announcements from Nvidia's CEO regarding new AI processors and storage technology [3] - Semiconductor stocks performed exceptionally well, with SanDisk surging over 27%, Western Digital up 17%, Seagate Technology rising 14%, and Micron Technology increasing by 10% [3] - The Philadelphia Semiconductor Index rose by 2.75%, marking a historical record with a cumulative gain of approximately 8% in the first three trading days of the year [3] Technology Sector - Large tech stocks showed mixed performance, with Amazon leading at a 3.38% increase, followed by Microsoft at 1.20%. However, Tesla fell sharply by 4.14%, and Nvidia declined by 0.47% [3] - Chinese concept stocks faced pressure, with the Nasdaq Golden Dragon China Index dropping by 0.78%. Notable movements included a 70.83% surge in Zhongchi Chefu and a 3.18% increase in ASE Technology [4] Commodity Market - Gold prices continued to rise, with spot gold increasing by 0.8% to $4485.39 per ounce [5] - International oil prices retreated, with light crude oil futures for February delivery falling by 2.04% to $57.13 per barrel [5] Regulatory Developments - The Chinese Ministry of Commerce announced stricter export controls on dual-use items to Japan, effective immediately, to safeguard national security [6] - The People's Bank of China outlined its monetary policy for 2026, emphasizing a moderately loose approach and support for economic development and financial stability [6] Financial Sector Insights - Financial institutions anticipate an improvement in market liquidity due to increased credit issuance and fiscal fund allocation at the beginning of the year [9] - Analysts suggest that the Shanghai Composite Index may experience slight upward fluctuations, urging investors to monitor macroeconomic data and policy changes closely [9]

证券代码：600721 证券简称：百花医药（维权） 公告编号：2026-001 新疆百花村医药集团股份有限公司 关于终止筹划控制权变更事项暨复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 证券停复牌情况：适用 因新疆百花村医药集团股份有限公司（以下简称"百花医药"或"公司"）控股股东、实际控制人米在齐先 生、米恩华先生、杨小玲女士终止筹划本次控制权变更事项,本公司的相关证券停复牌情况如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，本着审慎的原 则，决定终止本次控制权变更事项。 公司目前各项经营情况正常，终止筹划控制权变更事项不会对公司经营业绩和财务状况产生重大不利影 响。 三、复牌安排 ■ 一、停牌情况概述 因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正在筹划公司股份协议转让事宜， 该事项可能导致公司控制权发生变更。鉴于该事项正在洽谈当中，尚存在不确定性，为保证公平信息披 露，维护投资者利益， ...

Group 1: Company Updates - ChaoYing Electronics has adjusted the investment amount for its AI computing power high-end printed circuit board expansion project from 1.468 billion RMB to 3.315 billion RMB, aiming to meet stronger demand for high-end PCB products and enhance overseas production capabilities [2] - Baihua Pharmaceutical and Siwei Control have both terminated their plans for control change due to a lack of consensus with the transaction parties, with their stocks set to resume trading on January 7, 2026 [3] - Aihui Long has signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products through its strong sales channels in emergency, brain disease diagnosis, and pediatrics [10] Group 2: Performance Forecasts - Zhongtai Co. expects a net profit of 420 million to 480 million RMB for 2025, recovering from a loss of 77.96 million RMB in the previous year due to improved operations of its subsidiary [5] - Lier Chemical anticipates a net profit of 460 million to 500 million RMB for 2025, representing a year-on-year growth of 113.62% to 132.19% due to increased demand for its products [5] Group 3: Financing and Restructuring - Zhejiang Xiantong plans to issue A-shares to no more than 35 specific investors, raising up to 1.05 billion RMB for smart manufacturing projects and working capital [7] - Longjing Environmental Protection has received acceptance from the Shanghai Stock Exchange for its securities issuance application, pending further approvals [8] Group 4: Strategic Partnerships - Fushite has signed a strategic cooperation agreement with Jiangxi Copper Group to enhance collaboration in mining equipment maintenance and expand overseas market development [15] - Pro Pharmaceutical has entered into a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., focusing on long-term collaboration in innovative drug research and outsourced production [15] Group 5: Market Activity and Stock Performance - Jia Mei Packaging's stock price increased by 230.48% from December 17, 2025, to January 6, 2026, prompting a temporary suspension for investigation due to significant price volatility [11] - Guosheng Technology's stock experienced a 370.20% increase from October 31, 2025, to January 6, 2026, leading to a suspension for review due to potential irrational market behavior [20]

Group 1 - The core viewpoint of the article is the announcement of the termination of control right change plans by Baohua Pharmaceutical and Siwei Liekong, indicating stability in their operations and financial conditions [3][6][10]. Group 2 - Baohua Pharmaceutical's stock was suspended on December 29, 2025, due to potential control right changes, with a recent market capitalization of 4.707 billion [4][13]. - Prior to suspension, Baohua Pharmaceutical's stock price increased by 6.54% and 5.88% in the two trading days leading up to the announcement [4][13]. - For the first three quarters of 2025, Baohua Pharmaceutical reported revenue of 299 million, a year-on-year increase of 2.74%, and a net profit of 32.67 million, up 36.41% year-on-year [6]. Group 3 - Siwei Liekong's stock was also suspended on December 29, 2025, with a total market capitalization of 10.6 billion [7][9]. - The company stated that the termination of the control right change plan would not have a significant adverse impact on its operational performance and financial status [10].

Company Announcements - Jia Mei Packaging's stock price increased by 230% from December 17, 2025, to January 6, 2026, leading to a suspension for investigation starting January 7, 2026 [2] - Guosheng Technology's stock rose by 370.2% during the same period, prompting a suspension for investigation effective January 7, 2026 [3] - Fenglong Co., Ltd. indicated that it may apply for a suspension if its stock price continues to rise abnormally [4] - Xinfang Pharmaceutical is facing public prosecution for alleged unit bribery [7] - Shengke Communication's second-largest shareholder plans to reduce its stake by no more than 3% [8] - Chip Origin Technology completed the acquisition of Zhudian Semiconductor [9] - Robotech's subsidiary signed a significant contract for automatic optical switch packaging with a Swiss client [10] - Aerospace Changfeng clarified that it does not engage in brain-computer interface or commercial aerospace businesses [12] - Chengjian Development holds 18.91 million shares of Century Space, making it the fourth-largest shareholder [13] - Sanbo Brain Science is not involved in the research, production, or sales of brain-computer interface products [14] - Weisi Medical's new products in the brain-computer interface field are still in the early market cultivation stage [16] - Mairande's products in the brain-computer interface area are also in the research and market cultivation phase [17] - Guankang Technology plans to acquire 100% of Liaojing Electronics, with stock resuming trading [19] - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Star Chain to expand its presence in the brain-computer interface field [20] - China Satellite Communications warned that its stock price is at a historical high and may experience a significant drop [21] - Beidou Star Communication stated that commercial aerospace is just one application scenario for its products and services [22] Financial Performance - Lier Chemical expects a net profit increase of 113.62% to 132.19% for 2025 [39] - Zhongtai Co., Ltd. anticipates a net profit of 420 million to 480 million yuan for 2025, recovering from a previous loss [38] Financing and Capital Increase - Desai Xiwai is planning to issue H-shares and list on the Hong Kong Stock Exchange [40] - Xingye Yinx is also preparing to issue H-shares for listing on the Hong Kong Stock Exchange [41] Other Significant Events - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a shareholding increase commitment [42] - *ST Changyao's stock may face termination of listing due to negative net assets and other financial issues [43]

Core Viewpoint - Baihua Pharmaceutical (600721) announced the termination of the planned change in control due to a lack of consensus with the counterparties, and the company's stock will resume trading on January 7, 2026 [1][2]. Group 1: Control Change Announcement - The controlling shareholders and actual controllers, Mi Naqi, Mi Enhua, and Yang Xiaoling, decided to terminate the control change due to disagreements on significant matters [1]. - The company had previously announced a potential share transfer that could lead to a change in control, prompting a temporary suspension of trading to ensure fair information disclosure and protect investor interests [1]. Group 2: Business Operations and Financial Performance - The company stated that the termination of the control change will not have a significant adverse impact on its operational performance and financial status [2]. - Baihua Pharmaceutical's main business includes early drug discovery, CMC development, clinical trials, registration applications, and various pharmaceutical services, providing comprehensive outsourcing and technology transfer services [2]. - For the first three quarters of 2025, the company reported revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year growth of 36.41% [3].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：资本秘闻 终止控制权变更，百花医药（维权）（600721）1月7日起复牌。 1月6日晚间，百花医药发布公告称，因公司控股股东、实际控制人米在齐、米恩华、杨小玲终止筹划本 次控制权变更事项，经公司向上交所申请，公司股票将于1月7日开市起复牌。 百花医药表示，由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意 见，本着审慎的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变 更事项不会对公司经营业绩和财务状况产生重大不利影响。 责任编辑：杨红卜 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：资本秘闻 终止控制权变更，百花医药（维权）（600721）1月7日起复牌。 1月6日晚间，百花医药发布公告称，因公司控股股东、实际控制人米在齐、米恩华、杨小玲终止筹划本 次控制权变更事项，经公司向上交所申请，公司股票将于1月7日开市起复牌。 百花医药表示，由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意 见，本着审慎的原则，决定终止本次控制 ...

Macro Dynamics - China has discovered 1,444.49 tons of gold, with plans for a new round of mineral exploration starting in 2026, aiming to enhance the exploration and development of strategic mineral resources [2] - The Ministry of Commerce emphasizes the need for a collaborative approach among government, enterprises, and consumers to promote green consumption policies effectively [3] - The 2026 National Civil Aviation Work Conference highlighted the progress in domestic aircraft development, including the certification of new models and international market expansion [4] Financial Institutions - Bank of America predicts that AI chip stocks will continue to rise, with Nvidia, Broadcom, and AMD identified as top picks as the global semiconductor market is expected to exceed $1 trillion, with a projected 30% year-on-year sales growth in 2026 [7] Market Data - The Shanghai Composite Index reached a ten-year high with a 1.5% increase, and the total trading volume in the Shanghai and Shenzhen markets exceeded 2.8 trillion yuan, marking a significant increase in market activity [8] - As of January 5, the financing balance on the Shanghai Stock Exchange was reported at 1,277.036 billion yuan, reflecting an increase of 8.24 billion yuan from the previous trading day [9] - The Hong Kong Hang Seng Index rose by 1.38%, with significant gains in the brokerage and metals sectors [10] Company Dynamics - WuXi AppTec announced that shareholders controlled by the actual controller have reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital [12] - Jia Mei Packaging's stock surged by 230% from December 17, 2025, to January 6, 2026, leading to a temporary suspension for price verification [13] - Samsung Electronics is expected to see a 160% year-on-year increase in operating profit for Q4 2025, driven by a surge in demand for storage chips due to the AI boom [14] - Alibaba's AI model for early pancreatic cancer screening has successfully identified cases that may have been missed, showcasing the potential of AI in healthcare [18] - Aerospace company Hangtian Huanyu anticipates that its commercial space revenue will account for less than 15% of total revenue in 2025, with a slight net profit growth of 0.56% year-on-year [19]

百花医药表示，由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意 见，本着审慎的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变 更事项不会对公司经营业绩和财务状况产生重大不利影响。 北京商报讯（记者 丁宁）1月6日晚间，百花医药（600721）发布公告称，因公司控股股东、实际控制 人米在齐、米恩华、杨小玲终止筹划本次控制权变更事项，经公司向上交所申请，公司股票将于1月7日 开市起复牌。 ...

智通財經APP訊，百花醫藥(600721.SH)公告，公司控股股東、實際控制人米在齊先生、米恩華先生、 楊小玲女士終止籌劃控制權變更事項。公司股票將於2026年1月7日(星期三)開市起復牌。 ...